These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7886659)

  • 21. [Investigation of cytomegalovirus positivity in the peripheral blood samples of risky patients by shell-vial cell culture, antigenemia test and real-time polymerase chain reaction].
    Gökahmetoğlu S; Yağmur G; Mutlu Sarıgüzel F; Deniz E
    Mikrobiyol Bul; 2011 Apr; 45(2):288-95. PubMed ID: 21644072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
    Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK
    Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The correlation between symptomatic CMV infection and CMV antigenemia in heart allograft recipients.
    Koskinen PK; Nieminen MS; Mattila SP; Häyry PJ; Lautenschlager IT
    Transplantation; 1993 Mar; 55(3):547-51. PubMed ID: 8384383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes.
    van der Bij W; Torensma R; van Son WJ; Anema J; Schirm J; Tegzess AM; The TH
    J Med Virol; 1988 Jun; 25(2):179-88. PubMed ID: 2839611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytomegalovirus load in whole blood is more reliable for predicting and assessing CMV disease than pp65 antigenaemia.
    Hardie DR; Korsman SN; Hsiao NY
    J Virol Methods; 2013 Oct; 193(1):166-8. PubMed ID: 23792685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins.
    Gerna G; Revello MG; Percivalle E; Zavattoni M; Parea M; Battaglia M
    J Clin Microbiol; 1990 Dec; 28(12):2681-8. PubMed ID: 2177748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study.
    Gerna G; Baldanti F; Torsellini M; Minoli L; Viganò M; Oggionnis T; Rampino T; Castiglioni B; Goglio A; Colledan M; Mammana C; Nozza F; Daniele L;
    Antivir Ther; 2007; 12(1):63-72. PubMed ID: 17503749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients.
    Schulz U; Solidoro P; Müller V; Szabo A; Gottlieb J; Wilkens H; Enseleit F
    Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S5-10. PubMed ID: 26900992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative cytomegalovirus (CMV) antigenaemia during antiviral treatment of AIDS-related CMV disease.
    Manfredi R; Lazzarotto T; Spezzacatena P; Dal Monte P; Mastroianni A; Coronado OV; Chiodo F
    J Antimicrob Chemother; 1997 Aug; 40(2):299-302. PubMed ID: 9302001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview.
    Grossi P; Mohacsi P; Szabolcs Z; Potena L
    Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S1-4. PubMed ID: 26900989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of nested PCR and quantitative real time PCR for cytomegalovirus detection in renal transplant recipients.
    Kanaan A; Cour I; Alvarez-Lafuente R; Benedicto M; Culebras E; Prats D; Fernández C; Picazo JJ
    Int J Antimicrob Agents; 2004 Nov; 24(5):455-62. PubMed ID: 15519477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative measurement of cytomegalovirus-specific IgG and IgM antibodies in relation to cytomegalovirus antigenaemia and disease activity in kidney recipients with an active cytomegalovirus infection.
    Van der Giessen M; van den Berg AP; van der Bij W; Postma S; van Son WJ; The TH
    Clin Exp Immunol; 1990 Apr; 80(1):56-61. PubMed ID: 2157567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of CMV-specific T helper responses in lung transplant recipients.
    Zeevi A; Morel P; Spichty K; Dauber J; Yousem S; Williams P; Grgurich W; Pham S; Iacono A; Keenan R; Duquesnoy R; Griffith B
    Hum Immunol; 1998 Dec; 59(12):768-75. PubMed ID: 9831132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cytomegalovirus antigenemia assay: a plea for standardization.
    The TH; van den Berg AP; Harmsen MC; van der Bij W; van Son WJ
    Scand J Infect Dis Suppl; 1995; 99():25-9. PubMed ID: 8668937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cytomegalovirus infection after transplantation. Virological diagnosis, antiviral treatment].
    Freymuth F; Petitjean J; Eugene-Ruelland G; Daon F; Galateau F
    Pathol Biol (Paris); 1993 Oct; 41(8):724-30. PubMed ID: 8290319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of human cytomegalovirus gene expression in thoracic organ transplant recipients using nucleic acid sequence-based amplification.
    Oldenburg N; Lam KM; Khan MA; Top B; Tacken NM; McKie A; Mikhail GW; Middeldorp JM; Wright A; Banner NR; Yacoub M
    Transplantation; 2000 Oct; 70(8):1209-15. PubMed ID: 11063343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection improvement of cytomegalovirus antigen in human peripheral blood using monoclonal antibodies and automated reading of cell preparations.
    Boland GJ; Mesker WE; Doorn R; Ploem-Zaaijer JJ; Tank HJ; de Gast GC
    Eur J Clin Invest; 1995 Sep; 25(9):639-46. PubMed ID: 7498236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blinded, prospective study to define antigenemia and quantitative real-time polymerase chain reaction cutoffs to start preemptive therapy in low-risk, seropositive, renal transplanted recipients.
    David-Neto E; Triboni AH; Paula FJ; Vilas Boas LS; Machado CM; Agena F; Latif AZ; Alencar CS; Pierrotti LC; Nahas WC; Caiaffa-Filho HH; Pannuti CS
    Transplantation; 2014 Nov; 98(10):1077-81. PubMed ID: 24839894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence, Risk Factors and Outcomes of Delayed-onset Cytomegalovirus Disease in a Large Retrospective Cohort of Lung Transplant Recipients.
    Santos CA; Brennan DC; Yusen RD; Olsen MA
    Transplantation; 2015 Aug; 99(8):1658-66. PubMed ID: 25675196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitation of human cytomegalovirus DNA in bone marrow transplant recipients.
    Gerna G; Furione M; Baldanti F; Percivalle E; Comoli P; Locatelli F
    Br J Haematol; 1995 Nov; 91(3):674-83. PubMed ID: 8555075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.